“…It has also been shown that regular subcutaneous infusions allow for keeping the IgG level more stable. Pharmacokinetically, SCIG has a flatter serum concentration profile compared with IVIG, minimizing the potential risk of systemic adverse events (AEs) from initially high peak values or 'wearing-off' effects from low trough values at the end of a 3-to 4-week dosing interval [5,10,17,20]. In a randomized, cross-over study by Chapel, the number and severity of infections were the same during IVIG and SCIG therapy [3].…”